MAM is the new go-to for biotherapeutic development and manufacturing. It improves understanding of product and process, ensuring quality, safety, and efficacy. Biopharmaceutical companies are exploring its potential to replace multiple conventional assays for commercial QC testing. However, challenges arise in QC laboratories due to a lack of expertise, compliance requirements, and system performance. Our collaborators at National Institute of Bioprocessing Research and Training (NIBRT) conducted a study showcasing MAM's repeatability, reproducibility, and linearity analysis for selected CQAs. Discover more about this study and MAM's benefits in QC release assays by filling out the form below.

Please complete this form to download NIBRT’s case study

* Required field

Style Sheet for Global Design System
CMD Wide-format style fixes